Abstract:Introduction: Vedolizumab (VDZ) is a gut-selective anti-lymphocyte trafficking (GSALT) biologic, which binds to the α4β7 integrin and reduces intestinal tissue inflammation. VDZ was approved to treat moderate to severe Ulcerative Colitis (UC) and Crohn's disease (CD) patients (pts) in China in 2020; however, the effectiveness and safety of VDZ in Chinese Inflammatory bowel disease (IBD) pts are lacking. Methods: VALUE study is a prospective, multicenter, single-armed observational study to evaluate the safety and effectiveness of VDZ in the Chinese population, with a study sample size of 750 IBD pts. This study evaluated the safety of VDZ in adult IBD pts during a maximum of 72-week observation period; and the effectiveness of VDZ, including clinical response, clinical remission, and endoscopic remission, at week 14, 30 and 54. Two interim analysis for safety and effectiveness monitoring purposes were planned. This is the first interim analysis in UC pts. A descriptive summary was provided for demographic and baseline characteristics, safety, and effectiveness. Results: Totally 245 UC pts were enrolled in this interim analysis. 86.12% (211/245) UC pts were included in the effectiveness analysis set. The mean age was 45.6 years old. 60.82% (149/245) pts were male. Most UC pts were extensive UC (48.16%). The median duration of UC was 1035 days. 10.61% (26/245) pts had prior biologic use, the Partial Mayo mean (±SD) score was 5.185 (±1.936) (Table 1). After initiation of VDZ treatment, 79.19% (118/149) and 82.09% (55/67) pts achieved clinical response at week 14 and 30, respectively. 66.89% (101/151) and 71.64% (48/67) pts achieved clinical remission at week 14 and 30, respectively. 76.32% (29/38) and 76.47% (13/17) pts achieved endoscopic remission at week 14 and 30, respectively. 26.32% (10/38) and 29.41% (5/17) pts achieved complete endoscopic remission at week 14 and 30, respectively (Figure 1). At week 54, 2 of 2 pts achieved clinical remission and 1 of 1 pts achieved complete endoscopic remission. The performance of VDZ in the subgroup population was similar to that of the overall population, and both had promising efficacy (Figure ). Most (70.16%) of adverse events during the treatment were mild, 2.04% of patients had adverse events leading to study discontinuation, and no new safety signals were observed. Conclusion: Vedolizumab was effective and well tolerated in Chinese UC pts in the real-world setting. Further studies are needed to consolidate this result.Figure 1.: Clinical outcomes of UC patients after 14 and 30 weeks of VDZ therapy. a: Clinical response defined as ≥2 points reduction in Partial Mayo Clinic score and ≥25% decrease from baseline score accompanied with ≥1-point decrease in rectal bleeding sub-score or absolute rectal bleeding sub-score ≤1; b: Clinical remission defined as Partial Mayo Clinic score ≤2 with no sub-score >1; c: Endoscopic remission defined as Mayo endoscopic sub-score ≤1; d: Complete endoscopic remission defined as Mayo endoscopic sub-score of 0. Table 1. - Baseline Demographic Characteristics Patient characteristic UC (N=245) Age, years, mean (SD) 45.6 (14.79) Male, n (%) 149 (60.82%) Partial Mayo score, mean (SD) 5.185 (1.936) Duration of UC, days, median 1035 Disease location of UC patients, n (%) E1 - Ulcerative proctitis 39 (15.92%) E2 - Left sided UC (distal UC) 61 (24.90%) E3 - Extensive UC (pancolitis) 118 (48.16%) Unknown 21 (8.57%) Other 6 (2.45%) Any patients having UC-related surgery, n (%) 8 (3.27%) Colectomy 3 (1.22%) Ileocolectomy 1 (0.41%) Ostomy (colostomy or ileostomy) 0 (0.00%) Other 6 (2.45%) Any patient with prior medication, n (%) 213 (86.94%) 5-ASA 163 (66.53%) Steroids 54 (22.04%) IMM 7 (2.86%) Biologics 26 (10.61%) Adalimumab 2 (0.82%) Infliximab 21 (8.57%) Interleukin 12/23 inhibitor 2 (0.82%) Other biologics 1 (0.41%) Other medications 100 (40.82%)

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies

Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn’s Disease

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies

The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

S1231 Real-World Effectiveness and Onset of Action of Vedolizumab as a First-Line Biologic in Biologic-Naïve Patients With Ulcerative Colitis

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China.

P776 A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-world Clinical Practice in China: Interim Analysis of Safety results

P629 Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

P628 Vedolizumab in Indian patients with Inflammatory Bowel Disease: Interim results from a prospective, multicentre, open-label, phase 4 study

S288 Clinical Effectiveness of Vedolizumab in Chinese Ulcerative Colitis Patients: Results from the VALUE Study

Vedolizumab As Induction and Maintenance Therapy for Ulcerative Colitis

P990 A Multi-center, Single-arm, Prospective, Observational, Real-world Study in China to Evaluate Effectiveness of Vedolizumab in the Treatment of Inflammatory Bowel Diseases: First Interim Analysis of Patient-reported Outcomes

P627 Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease by disease location: Results from the EVOLVE Expansion study

Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis

P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study

P959 Dose escalated vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

P922 A multicenter retrospective real-world study to determine the optimal cases of vedolizumab-treated UC patients